Cargando…

Differential diagnosis of demyelinating diseases: what's new?

BACKGROUND: Acquired demyelinating disorders lead to overlapping visual, pyramidal, sensory, autonomic, and cerebellar deficits and may lead to severe disability. Early diagnosis and start of treatment are fundamental towards preventing further attacks and halting disability. OBJECTIVE: In this pape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomes, Ana Beatriz Ayroza Galvão Ribeiro, Adoni, Tarso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academia Brasileira de Neurologia - ABNEURO 2022
Materias:	Inflammatory and Demyelinating Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491438/ https://www.ncbi.nlm.nih.gov/pubmed/35976299 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S109

Ejemplares similares

Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
por: Silva, Guilherme Diogo, et al.
Publicado: (2022)

How to choose initial treatment in multiple sclerosis patients: a case-based approach
por: Apóstolos, Samira Luisa Pereira, et al.
Publicado: (2022)

A critical review and update on autoimmune encephalitis: understanding the alphabet soup
por: Simabukuro, Mateus Mistieri, et al.
Publicado: (2022)

Plasma Exchange for Treatment of Refractory Demyelination
por: Cronin, Michael, et al.
Publicado: (2020)

Axonal Damage in Pediatric Multiple Sclerosis
por: Kuntz, Nancy L.
Publicado: (2015)

MRI to Discriminate Pediatric MS from ADEM
por: Rubin, Jennifer P.
Publicado: (2015)

Relation of Posterior Cerebellar Volume to Cognition in MS
por: Millichap, J. Gordon
Publicado: (2015)

Prognostic Factors of MS Conversion in Optic Neuritis
por: Fajardo, Marytery, et al.
Publicado: (2015)

Quality of Life in Multiple Sclerosis
por: Williams, Mitchell T., et al.
Publicado: (2020)

Inflammatory bowel disease cross‐sectional imaging: What's new?
por: Wang, Yang‐di, et al.
Publicado: (2022)

The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis
por: Zheng, Jiaying, et al.
Publicado: (2022)

Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC
por: Starr, Amanda E, et al.
Publicado: (2017)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease
por: Qasem, Ahmad, et al.
Publicado: (2019)

Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis
por: Lundberg Båve, Aiva, et al.
Publicado: (2023)

SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation
por: Južnić, Lea, et al.
Publicado: (2021)

Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN
por: Gorelik, Yuri, et al.
Publicado: (2022)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Surfing the web as a patient with IBD: New horizons
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2023)

Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study
por: Klepp, Pasquale, et al.
Publicado: (2020)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
por: Fischer, Anika, et al.
Publicado: (2016)

Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience
por: Barreiro‐de Acosta, Manuel, et al.
Publicado: (2021)

Identifying and understanding disease burden in patients with inflammatory bowel disease
por: Christensen, Katrine Risager, et al.
Publicado: (2022)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
por: Fernandes, Samuel Raimundo, et al.
Publicado: (2022)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Does colectomy in UC patients impact on the PSC onset?: A national registry brings new insights
por: Liefferinckx, Claire
Publicado: (2023)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

Changing paradigms in management of inflammatory bowel disease
por: Mao, Ren, et al.
Publicado: (2022)

Environmental risk factors for inflammatory bowel disease
por: Singh, Noreen, et al.
Publicado: (2022)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Effectiveness of disease-specific cognitive–behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD)
por: van den Brink, Gertrude, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f8vqvna0mk044tg1ikk3afa6t9